trending Market Intelligence /marketintelligence/en/news-insights/trending/1UvygquovynXT3IpaqpR3w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neovasc wins full rights to heart device against Edwards in German court

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Neovasc wins full rights to heart device against Edwards in German court

Neovasc Inc. said a German court dismissed a case brought by Edwards Lifesciences Corp. against the company, reverting the full ownership rights to a European patent related to the Tiara heart device.

A lower court in Munich had awarded co-ownership rights to the patent to both Neovasc and Edwards Lifesciences, a decision the parties appealed. However, Edwards Lifesciences withdrew its appeal for full ownership during the appeal process.

Tiara is a medical device used for treating mitral valve regurgitation by replacing the diseased valve. Mitral regurgitation is a condition in which the heart's mitral valve does not close tightly, allowing blood to flow backward in the heart.

Canada's Neovasc noted that the German court, while dismissing the case, found that Edwards Lifesciences had not contributed to the invention of Tiara — leaving the ownership rights of the device with the medical-device maker.

The decision allows Neovasc to pursue its European patent application with the sole right to commercialize Tiara in the region. The decision can be appealed by the parties in the German Supreme Court.

In the U.S., Irvine, Calif.-based medical-device maker Edwards Lifesciences has won a patent case against Neovasc related to the Tiara program.